Article Text

Download PDFPDF
Serum osteoprotegerin but not receptor activator of NF-κB ligand correlates with Larsen score in rheumatoid arthritis
  1. M Skoumal1,
  2. G Kolarz1,
  3. W Woloszczuk2,
  4. G Hawa3,
  5. A Klingler4
  1. 1Institut für Rheumatologie der Kurstadt Baden in Kooperation mit der Donauuniversität Krems, Rheumasonder-krankenanstalt der SVA der gewerblichen Wirtschaft, Baden, Austria
  2. 2Ludwig Boltzmann Institut für experimentelle Endokrinologie, Vienna, Austria
  3. 3Biomedica Medizinprodukte GmbH & Co KG, Austria
  4. 4Theoretical Surgery Unit, Department of General and Transplant Surgery, University Hospital, Innsbruck, Austria
  1. Correspondence to:
    Dr M Skoumal
    Rheumasonderkrankenanstalt der SVA der gewerblichen Wirtschaft, Adolfine Malchergasse 1, 2500 Baden, Austria;

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Osteoprotegerin (OPG) is a soluble decoy receptor, produced by osteoblastic cells and in the inflamed synovium of RA by dendritic cells, B cells, and other immunocompetent cells.1,2 It inhibits the differentiation of osteoclast precursor cells and the activation of mature osteoclasts by neutralising the receptor activator of NF-κB ligand (RANKL).3

RANKL, a member of the tumour necrosis factor family, is expressed on prae-osteoblasts and T lymphocytes. A soluble RANKL (sRANKL) can be produced by activated T lymphocytes or can be generated from the cell bound form by a protease. RANKL itself activates a receptor activator of NF-κB (RANK).4

RANKL, together with monocyte-colony stimulating factor, interleukin 1, and RANK is responsible for osteoclast formation and activation and inhibits …

View Full Text